A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Launched by BRISTOL-MYERS SQUIBB · Apr 22, 2024

Keywords

ClinConnect Summary

This clinical trial, called RePhlect, is studying how effective a new medication called deucravacitinib is for adults in Japan who have plaque psoriasis, a skin condition that causes red, scaly patches. The trial will compare the results of patients taking deucravacitinib with those taking another treatment called apremilast. The goal is to see which medication works better in real-world settings.

To participate, you must be at least 18 years old and have been diagnosed with plaque psoriasis by a doctor. You also need to be starting treatment with either deucravacitinib or apremilast for the first time. The study is currently looking for participants, so if you qualify and decide to join, you’ll be monitored to see how well the medication helps your condition. It's important to note that if you are already in another clinical trial or have previously used either of these treatments, you won't be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Japanese adult participants aged 18 years old or older
• • Physician-reported diagnosis of plaque psoriasis
• • Newly initiating deucravacitinib or apremilast according to the label
• • Participants who have signed informed consent
• Exclusion Criteria:
• • Participants currently participating in or planning to participate in an interventional clinical trial
• • Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264)
• • Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)